RT Journal Article
SR Electronic
T1 The overlap of genetic susceptibility to schizophrenia and cardiometabolic disease can be used to identify metabolically different groups of individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.23.20138271
DO 10.1101/2020.06.23.20138271
A1 Strawbridge, Rona J.
A1 Johnston, Keira J. A.
A1 Bailey, Mark E. S.
A1 Baldasarre, Damiano
A1 Cullen, Breda
A1 Eriksson, Per
A1 DeFaire, Ulf
A1 Ferguson, Amy
A1 Gigante, Bruna
A1 ,
A1 Giral, Philippe
A1 Graham, Nicholas
A1 Hamsten, Anders
A1 Humphries, Steve E.
A1 Kurl, Sudhir
A1 Lyall, Donald M.
A1 Lyall, Laura M.
A1 Pirro, Matteo
A1 Pell, Jill P.
A1 Savonen, Kai
A1 Sennblad, Bengt
A1 Smit, Andries J.
A1 Tremoli, Elena
A1 Tomainen, Tomi-Pekka
A1 Veglia, Fabrizio
A1 Ward, Joey
A1 Smith, Daniel J.
YR 2020
UL http://medrxiv.org/content/early/2020/06/24/2020.06.23.20138271.abstract
AB Understanding why individuals with severe mental illness (Schizophrenia, Bipolar Disorder and Major Depressive Disorder) have increased risk of cardiometabolic disease (including obesity, type 2 diabetes and cardiovascular disease), and identifying those at highest risk of cardiometabolic disease are important priority areas for researcher. We explored whether genetic variation could identify individuals with different metabolic profiles. Loci previously associated with schizophrenia, bipolar disorder and major depressive disorder were identified from literature and those overlapping loci genotyped on the Illumina CardioMetabo and Immuno chips (representing cardiometabolic processes and diseases) were selected. In the IMPROVE study (high cardiovascular risk) and UK Biobank (general population) multidimensional scaling was applied to genetic variants implicated in both mental and cardiometabolic illness. Visual inspection of the resulting plots used to identify distinct clusters. Differences between clusters were assessed using chi-squared and Kruskall-Wallis tests. In IMPROVE, genetic loci associated with both cardiometabolic disease and schizophrenia (but not bipolar or major depressive disorders) identified three groups of individuals with distinct metabolic profiles. The grouping was replicated in UK Biobank, albeit with less distinction between metabolic profiles. This study provides proof of concept that common biology underlying mental and physical illness can identify subsets of individuals with different cardiometabolic profiles.Competing Interest StatementThe authors have declared no competing interest.Funding StatementIMPROVE was supported by the European Commission (Contract number: QLG1-CT-2002-00896), the Swedish Heart-Lung Foundation, the Swedish Research Council (projects 8691 and 09533), the Knut and Alice Wallenberg Foundation, the Foundation for Strategic Research, the Stockholm County Council (project 592229), the Strategic Cardiovascular and Diabetes Programmes of Karolinska Institutet and Stockholm County Council, the European Union Framework Programme 7 (FP7/2007-2013) for the Innovative Medicine Initiative under grant agreement n IMI/115006 (the SUMMIT consortium), the Academy of Finland (Grant #110413), the British Heart Foundation (RG2008/08, RG2008/014) and the Italian Ministry of Health (Ricerca Corrente). The UK Biobank was established by the Wellcome Trust, Medical Research Council, Department of Health, Scottish Government and Northwest Regional Development Agency. UK Biobank has also had funding from the Welsh Assembly Government and the British Heart Foundation. Data collection was funded by UK Biobank. RoJS is supported by a UKRI Innovation-HDR-UK Fellowship (MR/S003061/1). LML is supported by the JMAS Sim Fellowship for depression research from the Royal College of Physicians of Edinburgh. AF is supported by an MRC Doctoral Training Programme Studentship at the University of Glasgow (MR/K501335/1). KJAJ is supported by an MRC Doctoral Training Programme Studentship at the Universities of Glasgow and Edinburgh. DJS acknowledges the support of a Lister Prize Fellowship (173096) and MRC Mental Health Data Pathfinder Award (MC_PC_17217). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IMPROVE study: All participants provided written informed consent and the study was conducted in accordance with the Helsinki Declaration. Ethical approval was granted by the regional ethics board for each recruitment centre. The UK Biobank: All participants provided written informed consent and ethical approval was granted by the NHS national Research Ethics Service.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.